LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

LeMaitre Vascular Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

85.61 -0.65

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

85.44

Max

87.63

Pagrindiniai rodikliai

By Trading Economics

Pajamos

3.6M

17M

Pardavimai

-3.2M

61M

P/E

Sektoriaus vid.

37.302

121.746

Dividendų pajamingumas

0.87

Pelno marža

28.441

Darbuotojai

651

EBITDA

4.5M

26M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+7.46% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.87%

2.26%

Kitas uždarbis

2026-02-25

Kitas dividendų mokėjimo data

2026-03-26

Kita Ex Dividend data

2026-03-12

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-4.4M

2B

Ankstesnė atidarymo kaina

86.26

Ankstesnė uždarymo kaina

85.61

Naujienos nuotaikos

By Acuity

50%

50%

149 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

LeMaitre Vascular Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-11 23:47; UTC

Karštos akcijos

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

2026-02-11 22:59; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Grab Holdings to Buy U.S.-Based Stash Financial

2026-02-11 23:54; UTC

Uždarbis

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

2026-02-11 23:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-11 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

2026-02-11 23:49; UTC

Uždarbis

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

2026-02-11 23:45; UTC

Uždarbis

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

2026-02-11 23:42; UTC

Uždarbis

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

2026-02-11 23:41; UTC

Uždarbis

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

2026-02-11 23:40; UTC

Uždarbis

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

2026-02-11 23:35; UTC

Rinkos pokalbiai

Gold Falls on Prospects of Long Fed Pause -- Market Talk

2026-02-11 23:18; UTC

Rinkos pokalbiai

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

2026-02-11 23:14; UTC

Rinkos pokalbiai

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

2026-02-11 22:59; UTC

Uždarbis

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

2026-02-11 22:59; UTC

Uždarbis

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

2026-02-11 22:59; UTC

Uždarbis

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

2026-02-11 22:58; UTC

Uždarbis

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

2026-02-11 22:57; UTC

Uždarbis

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

2026-02-11 22:54; UTC

Uždarbis

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

2026-02-11 22:53; UTC

Uždarbis

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

2026-02-11 22:47; UTC

Uždarbis

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026-02-11 22:47; UTC

Uždarbis

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026-02-11 22:23; UTC

Uždarbis

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

2026-02-11 22:22; UTC

Uždarbis

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

2026-02-11 22:22; UTC

Uždarbis

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

2026-02-11 22:19; UTC

Uždarbis

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

2026-02-11 22:18; UTC

Uždarbis

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

2026-02-11 22:18; UTC

Uždarbis

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

2026-02-11 22:18; UTC

Uždarbis

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

2026-02-11 22:16; UTC

Uždarbis

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Akcijų palyginimas

Kainos pokytis

LeMaitre Vascular Inc Prognozė

Kainos tikslas

By TipRanks

7.46% į viršų

12 mėnesių prognozė

Vidutinis 93 USD  7.46%

Aukščiausias 93 USD

Žemiausias 93 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines LeMaitre Vascular Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

1 ratings

0

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

78.565 / 91.76Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

149 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę LeMaitre Vascular Inc

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
help-icon Live chat